Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP1 | O60894 | 1/20 | 0.59 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.37 |
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | CCR3 | P51677 | 2/20 | 0.35 |
| ▸ | CALCA | P06881 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | ROS1 | P08922 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314750 | 1.00 | RAMP1 (0.59) | RAMP1CALCRLADRB2SLC6A5F10 | |
| SCHEMBL5248991 | 0.91 | RAMP1 (0.59) | RAMP1CALCRLADRB2SLC6A5HSD11B1 | |
| SCHEMBL3314129 | 0.87 | CALCRL (0.66) | RAMP1CALCRLADRB2SLC6A5HSD11B1 | |
| SCHEMBL3314116 | 0.87 | CALCRL (0.66) | RAMP1CALCRLADRB2SLC6A5HSD11B1 | |
| SCHEMBL4472276 | 0.87 | RAMP1 (0.56) | RAMP1CALCRLADRB2SLC6A5CALCA | |
| SCHEMBL4472279 | 0.85 | RAMP1 (0.55) | RAMP1CALCRLADRB2SLC6A5CALCA | |
| SCHEMBL4472287 | 0.85 | RAMP1 (0.55) | RAMP1CALCRLADRB2SLC6A5CALCA | |
| SCHEMBL4717116 | 0.84 | RAMP1 (0.62) | RAMP1CALCRLADRB2SLC6A5HSD11B1 | |
| SCHEMBL3309816 | 0.83 | RAMP1 (0.58) | RAMP1CALCRLSLC6A5CHRM1 | |
| SCHEMBL3312084 | 0.83 | RAMP1 (0.53) | RAMP1CALCRLADRB2SLC6A5CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | RAMP1 84/4885CALCRL 1/4885ADRB2 63/4885 |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | RAMP1 84/4885CALCRL 1/4885ADRB2 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.